Emmet Mc Cormacks bilde

Emmet Mc Cormack

Professor, Galensk Farmasi
  • E-postEmmet.Mc.Cormack@uib.no
  • Telefon+47 55 97 46 28
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Preclinical model development

Preclinical multimodal imaging

Pharmaceutical drug development


BMED 320: Methods in Medical Cell Biology

Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis. 2013 Feb 28;4:e516. doi: 10.1038/cddis.2013.39.

Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT.  Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines. PLoS One. 2013;8(2):e56276. doi: 10.1371/journal.pone.0056276. Epub 2013 Feb 11.

Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS.MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer. 2013 Jan 25. doi: 10.1002/ijc.28056. [Epub ahead of print] 

McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother. 2012 Dec 22. [Epub ahead of print]

McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT. Multiplexed monoclonal antibodies: a new strategy in preclinical time domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14;121(7):e34-e42 

McCormack E, Silden E, West RM, Pavlin T, Micklem DR, Lorens J, Haug BE, Cooper ME, Gjertsen BT. Nitroreductase, a near infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Res. 2013 Feb 15; 73(4):1276-1286 

Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H.Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One. 2012;7(11):e48992. 

Lee J, Li M, Milwid J, Dunham J, Vinegoni C, Gorbatov R, Iwamoto Y, Wang F, Shen K, Hatfield K, Enger M, Shafiee S, McCormack E, Ebert BL, Weissleder R, Yarmush ML, Parekkadan B. Implantable microenvironments to attract hematopoietic stem/cancer cells. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19638-43.

Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Prehn JH, Bjerkvig R, Byrne AT. In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of Glioblastoma Multiforme. Mol. Imaging 2013 Mar 1;12(2):1-12

Hjelle SM, Sulen A, Øye OK, Jørgensen K, McCormack E, Hollund BE andGjertsen BT. Leucocyte p53 protein biosignature through standard-aligned, two-dimensional immunoblotting. J Proteomics. 2012 Dec 5;76 Spec No.:69-78. 

Mujic M, Kotopoulis S, Delalande A, Enger M, Gilja OH, McCormack E, Postema M, Gjertsen BT. Flow cytometric characterisation and sorting of microbubble ultrasound contrast reagents. Marine and Medical Research 2012, 11:181-193

Karlsen TV, McCormack E, Mujic M, Tenstad O, Wiig H. Minimally invasive quantification of lymph flow in mice and rats by imaging depot clearance of near-infrared albumin. Am J Physiol Heart Circ Physiol. 2012 Jan;302(2):H391-401

McCormack E, Haaland I, Venås G, Brendsdal Forthun R, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud Ø, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012 May;26(5):910-7

Ke X, Li W, Hovland H, Qu Y, Liu R, McCormack E, Thorsen F, Rotter V, AkslenLA Oyan AM, Kalland KH. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and early malignant transformation in a prostate cell model. Exp Cell Res. 2011 Jan 15;317(2):234-47

Wang J, Daphu I, Pedersen PH, Miletic H, Hovland R, Mørk S, Bjerkvig R, Tiron C,McCormack E, Micklem D, Lorens JB, Immervoll H, Thorsen F. A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathol Appl Neurobiol. 2011 Feb;37(2):189-205.

Torsvik A, Molven A, Røsland GV, Svendsen A, Primon M, Sobala E, McCormack Eet al. Spontaneous Malignant Transformation of human Mesenchymal Stem Cells reflects cross-contamination; putting the research field on track. Cancer Res. 2010 Aug 1;70(15):6393-6. Epub 2010 Jul 14.

Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Lid S,McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackind C, and Lorens JB. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9.

Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leuk. Res2010 [Epub ahead of print].

McCormack E, Skavland J, Mujić M, Bruserud Ø, Gjertsen BT. Lentinan: Haematopoietic, immunological and efficacy studies in a syngeneic model of acute myeloid leukaemia. Nutr Cancer. 2010 Jul;62(5):574-83.

McCormack E*, Hofmann M*, Mujić M, Roßberg M, Bernd A, Bereiter-Hahn J, Gjertsen BT, Wiig H and Kippenberger S. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia 2009 ; 11(8):812-22

Røsland GV*, Svendsen A*, Torsvik A*, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lønning PE, Bjerkvig R, Schichor C. Long-term Cultures of Bone Marrow-Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation. Cancer Res. 2009;69(13):5331-9

Gjertsen BT, Mc Cormack E. Erythropoietin a safe bet in haemorrhagic shock? Acta Anaesthesiol Scand. 2008;52(5):585-6

McCormack E, Bruserud O, Gjertsen BT. Genetic Models of Acute Myeloid Leukemia. Oncogene. 2008; 27(27):3765-79

Gausdal G*, Gjertsen BT*, McCormack E, Doskeland SO, et al. Intact protein synthesis protects against anthracyclin-induced leukemia cell death in vitro and in intact animals. Blood. 2008 111(5):2866-77 *Joint authourship

McCormack E, Micklem D, Pindard LE, Silden E, Gallant P, Belenkov A, Lorens JB, Gjertsen BT. In vivo optical imaging of acute myeloid leukaemia (AML) by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification and localisation. Mol Imaging. 2007; 6(3):193-204

Ersvaer E, Zhang JY, McCormack E, Ånensen N, Eng MT, Gjertsen BT, Bruserud, O. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukaemia cells and serves as a leukaemia-associated antigen for a subset of patients. Eur J Haematol. 2007;79(3):210-25

Bruserud O, Trondstad KJ, McCormack E, Gjertsen BT. New strategies in the treatment of chronic lymphocytic leukaemia – what are the alternatives to immunotherapy. Cancer Immunol Immunother. 2006; 55(2): 221-8

Bruserud Ø, McCormack E, Gjertsen BT. Immunotherapy in chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006; 55(2): 185-7

McCormack E, Bruserud Ø, Gjertsen BT. Review: Animal models of acute myelogenous leukaemia-development, application and future perspectives. Leukemia 2005; 19(5), 687-706

Sjøholt G, Ånensen N, Wergeland L, Mc Cormack E, Bruserud Ø, Gjertsen BT Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targetsfor novel antileukaemic therapy. Curr Drug Targets.2005; 6(6): 631-46.

Mc Cormack E. Design, Synthesis and In Vitro evaluation of Novel Anti-Cancer Compounds. Dublin: Trinity College Dublin; 2002.

Walsh JJ, Shah R, Hudson GJ, McCormack E. Hybrid inhibitors for tumour angiogenesis/vasculature, [Patent application in Ireland 26th Sept 2008 P. 1-125] 


In vivo imaging of Cancer: Pharmaceutical and Diagnostic imaging 

Funding: Bergen Research Foundation (2011-2014)

More on the project here



Translational Optical Imaging Unit

Funding: Helse Vest




Translational Development of Preclinical Models and Therapies in Myeloid Neoplasia

Funding: Norwegian Cancer Society

Read more here



B.Sc. Applied Sciences (Chemistry and Mathematics) - D.I.T/Trinity College Dublin

Ph.D Pharmacy - Trinity College Dublin